论文部分内容阅读
经皮冠状动脉成形术(PTCA)已广泛应用于治疗有症状冠心病,但术后再狭窄的发生限制了其应用。冠脉内支架的应用使再狭窄率有所下降,但是再狭窄的防治仍然是一个新的、棘手的问题。以普罗布考和西洛他唑为代表的少数药物,临床试验证实其防治再狭窄作用显著,可望成为裸支架或药物洗脱支架重要辅助措施。本文综述再狭窄防治药物的临床研究进展,以期进一步了解再狭窄的防治途径。
Percutaneous transluminal coronary angioplasty (PTCA) has been widely used in the treatment of symptomatic coronary heart disease, but the occurrence of postoperative restenosis limits its application. The use of coronary stents reduces the rate of restenosis, but the prevention and treatment of restenosis is still a new and difficult issue. Probol and cilostazol represented by a small number of drugs, clinical trials confirmed its significant effect of restenosis, is expected to become a bare stent or drug-eluting stent important ancillary measures. This article reviews the progress of clinical research on restenosis prevention and treatment drugs in order to further understand the prevention and treatment of restenosis.